Small Molecule PPAR-alpha Agonism as a Novel Approach to Treat Eye Vascular Diseases
小分子 PPAR-α 激动剂作为治疗眼血管疾病的新方法
基本信息
- 批准号:10625310
- 负责人:
- 金额:$ 38.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAffinityAge related macular degenerationAgonistAngiogenesis InhibitorsAnimal ModelAntibodiesApoptosisAttenuatedBiochemicalBiological AssayBiological ProductsBlindnessBlood VesselsCell Culture TechniquesCellsCellular AssayClinicalClinical TrialsComplementComplexComplications of Diabetes MellitusDataDerivation procedureDevelopmentDiabetes MellitusDiabetic RetinopathyDiseaseDose LimitingDown-RegulationDrug KineticsDrug usageEndotheliumEpidemicEtiologyExhibitsExtravasationEyeFenofibrateFinancial HardshipGeneticHealth ExpendituresHealthcare SystemsHumanHyperlipidemiaImpairmentIn VitroInflammationInflammatoryInjectionsKnowledgeLeadLeukostasisLipidsMicrosomesMitochondriaModalityModelingMolecularNatureNerve DegenerationOperative Surgical ProceduresOxidative StressPPAR alphaPathologyPatientsPericytesPeroxisome Proliferator-Activated ReceptorsPersonsPharmaceutical PreparationsPopulationPopulation GrowthPrevalencePreventionProductionPropertyProtein IsoformsPublic HealthQuality of lifeRefractoryResearchResearch DesignRetinaRetinal DiseasesRetinal NeovascularizationRetinopathy of PrematurityRoleSecondary toStructureTherapeuticToxic effectType 2 diabeticUnited StatesVascular DiseasesVascular Endothelial Growth FactorsVisionaging demographicaging demographyanalogattenuationbevacizumabburden of illnessclinically relevantcomorbiditycompliance behaviordesigndiabeticdiabetic patientefficacy evaluationimprovedin silicoinnovationlead optimizationmeetingsmitochondrial dysfunctionneovascularizationneuroprotectionnovelnovel strategiesnovel therapeuticspatient populationpharmacologicprogramsprospectiveprotective effectresponseretinal toxicitysmall moleculestandard of caresuccesssynergismsystemic toxicitytool
项目摘要
Project Summary. Diabetic retinopathy (DR) is a common complication of diabetes and is the leading cause of
blindness in the working population. Currently, >40% of the patient population fails to respond to gold-standard
anti-VEGF direct intraocular injection treatments. New therapies that are superior to or synergistic with current
approaches are of great value to patients. Unlike current treatment options, new approaches should be non-
invasive (into the eye), affordable, and not reliant on specialized facilities. Our research program seeks to
develop small molecule PPARα agonists as first-in-class treatments for DR. The promise of PPARα agonism as
a novel strategy for treating DR has been confirmed in human clinical trials, wherein Fenofibrate (Feno), a
clinically used drug for hyperlipidemia, exhibited robust protective effects against DR and retinal
neovascularization (NV) in type 2 diabetic patients. We have determined that the protective effects of Feno are
unrelated to its lipid-lowering activity, but rather result from its agonism of PPARα. Feno however, suffers from
poor retinal distribution, low affinity/selectivity for PPARα, and chemotype related dose-limiting toxicities, all of
which will limit its use as a DR therapy. Recently, we have identified a novel class of non-fibrate PPARα agonists
that demonstrate improved potency and selectivity over Feno in vitro and exhibit efficacy in a retinal vascular
leakage DR animal model (i.p. administration). All totaled, these data provide proof-of-concept and clearly
demonstrate that 1) PPARα maintains critical roles in the major clinical features of DR and 2) Non-fibrate related
PPARα agonists with improved physicochemical properties and ocular distribution have high promise to become
first-in-class therapeutic options for DR. Specific Aims. (1) Structure-based hit to lead optimization of novel
PPARα agonists; (2) Determine the potency and efficacy of newly designed and synthesized analogs; (3) Define
the downstream molecular mechanism(s) underlying the protective effects of PPARα agonism against oxidative
stress and inflammation in DR. Study Design. We will leverage in silico PPARα models developed in our lab to
guide the design of improved agonists. Synthesized analogs will be assessed in in vitro biochemical and cellular
assays for PPARα potency, level of agonism, and isoform selectivity. Compounds meeting pre-defined metrics
will be advanced to secondary assays to determine anti-angiogenic, anti-oxidative, and neuroprotective effects
in vitro. Top compounds will be assessed for efficacy against retinal leukostasis, endothelial impairment, pericyte
loss, vascular leakage, visual function, and neuroretinal apoptosis in animal models. Top performing compounds
will be utilized for detailed studies to define the downstream molecular mechanisms underlying the protective
effects of PPARα agonism against the major etiological drivers of DR. The research is significant in that it will
provide new therapeutic leads and a novel approach for the treatment of DR, thus addressing a pressing global
need. The research is innovative in that it seeks to provide small molecule, non-invasive options for ocular
conditions typically treated with destructive surgical procedures or intraocular injections of biologics.
项目摘要。糖尿病性视网膜病(DR)是糖尿病的常见并发症,是
劳动人口的失明。目前,> 40%的患者人群无法对黄金标准做出反应
抗VEGF直接眼内注射治疗。与当前优越或协同作用的新疗法
方法对患者具有很高的价值。与当前的治疗方案不同,新方法应非
侵入性(进入眼睛),负担得起,不依赖专业设施。我们的研究计划试图
开发小分子PPARα激动剂作为DR的第一类治疗。 PPARα激动剂的承诺为
在人类临床试验中已经证实了一种治疗DR的新型策略,其中Fenobibrate(Feno),A
临床上使用的高脂血症药物,暴露于DR和视网膜的强大保护作用
2型糖尿病患者的新血管化(NV)。我们已经确定FENO的受保护作用是
与降脂活性无关,而是由于其PPARα的激动而引起的。 feno但是,
视网膜分布差,PPARα的亲和力/选择性低以及相关剂量限制性毒性的毒性较低
这将限制其用作博士疗法。最近,我们确定了一类新的非纤维化PPARα激动剂
这表明在视网膜血管中的体外和暴露效率方面提高了效力和选择性
泄漏DR动物模型(I.P.给药)。全部总计,这些数据提供了概念证明,并且清楚
证明1)PPARα在DR的主要临床特征和2)非纤维化相关的临床特征中保持关键作用
PPARα激动剂具有改善的物理特性和眼部分布具有很高的承诺
DR的第一类治疗选择。具体目标。 (1)基于结构的命中以优化新颖
PPARα激动剂; (2)确定新设计和合成类似物的效力和效率; (3)定义
PPARα激动剂对氧化作用的受保护作用的下游分子机制(S)
DR的压力和炎症。研究设计。我们将利用实验室开发的硅PPARα模型的利用
指导改进的激动剂的设计。合成的类似物将在体外生化和细胞中评估
PPARα效力,激动剂水平和同工型选择性的测定。符合预定义指标的化合物
将进行辅助测定,以确定抗血管生成,抗氧化和神经保护作用
体外。将评估顶部化合物的效率,以防止残留的白细胞症,内皮障碍,周围
动物模型中的损失,血管泄漏,视觉功能和神经视网膜凋亡。表现最高的化合物
将用于详细研究来定义受保护的下游分子机制
PPARα激动剂对DR的主要病因驱动因素的影响。这项研究很重要,因为它将
提供新的治疗潜在客户和一种新颖的方法来治疗DR,从而解决了紧迫的全球
需要。这项研究具有创新性,因为它试图为眼部提供小分子,无创选择
通常通过破坏性手术程序或生物制剂的眼内注射治疗的疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Adam Scott Duerfeldt其他文献
Adam Scott Duerfeldt的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Adam Scott Duerfeldt', 18)}}的其他基金
Small Molecule PPAR-alpha Agonism as a Novel Approach to Treat Eye Vascular Diseases
小分子 PPAR-α 激动剂作为治疗眼血管疾病的新方法
- 批准号:
10359598 - 财政年份:2020
- 资助金额:
$ 38.87万 - 项目类别:
Small Molecule PPAR-alpha Agonism as a Novel Approach to Treat Eye Vascular Diseases
小分子 PPAR-α 激动剂作为治疗眼血管疾病的新方法
- 批准号:
10412945 - 财政年份:2020
- 资助金额:
$ 38.87万 - 项目类别:
Hit to Lead Optimization of a Systemically Available Treatment for Diabetic Retinopathy
糖尿病视网膜病变的系统可用治疗方法的优化
- 批准号:
9375283 - 财政年份:2017
- 资助金额:
$ 38.87万 - 项目类别:
Structure, Function, and Therapeutic Potential of Clostridium difficile Caseinolytic Protease P (Duerfeldt)
艰难梭菌酪蛋白分解蛋白酶 P (Duerfeldt) 的结构、功能和治疗潜力
- 批准号:
9360240 - 财政年份:
- 资助金额:
$ 38.87万 - 项目类别:
相似国自然基金
基于计算生物学技术小分子农兽药残留物驼源单域抗体虚拟筛选与亲和力成熟 -以内蒙古阿拉善双峰驼为例
- 批准号:32360190
- 批准年份:2023
- 资助金额:34 万元
- 项目类别:地区科学基金项目
基于胞内蛋白亲和力标记策略进行新型抗类风湿性关节炎的选择性OGG1小分子抑制剂的发现
- 批准号:82304698
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于多尺度表征和跨模态语义匹配的药物-靶标结合亲和力预测方法研究
- 批准号:62302456
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
框架核酸多价人工抗体增强靶细胞亲和力用于耐药性肿瘤治疗
- 批准号:32301185
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
抗原非特异性B细胞进入生发中心并实现亲和力成熟的潜力与调控机制
- 批准号:32370941
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Developing a novel disease-targeted anti-angiogenic therapy for CNV
开发针对 CNV 的新型疾病靶向抗血管生成疗法
- 批准号:
10726508 - 财政年份:2023
- 资助金额:
$ 38.87万 - 项目类别:
Discovery of Cell-based Chemical Probes Targeting Aberrant Angiogenesis in the Eye
发现针对眼部异常血管生成的基于细胞的化学探针
- 批准号:
10453044 - 财政年份:2022
- 资助金额:
$ 38.87万 - 项目类别:
Sexual dimorphism in antigen-independent angiogenesis inhibition of IgG1 antibodies
IgG1 抗体的抗原非依赖性血管生成抑制中的性别二态性
- 批准号:
10536062 - 财政年份:2022
- 资助金额:
$ 38.87万 - 项目类别:
Sexual dimorphism in antigen-independent angiogenesis inhibition of IgG1 antibodies
IgG1 抗体的抗原非依赖性血管生成抑制中的性别二态性
- 批准号:
10705615 - 财政年份:2022
- 资助金额:
$ 38.87万 - 项目类别: